Disease Markers

Research Article

Human Paraoxonase-1 Activity Is Related to the Number of CD4+ T-Cells and Is Restored by Antiretroviral Therapy in HIV-1-Infected Individuals

Table 4

Laboratorial parameters and PON1 activity in HIV-1-infected individuals with highly active antiretroviral therapy (HAART) regimens and ART-naïve.
Parameters(1) Seronegative ( ) HIV-1-infected individuals ( ) value(2)
ART-naïve ( )EFV or NVP ( )LOP/r ( )
PON1 activity (U/L) 117 (68, 218)81 (51, 137)*109 (60, 159)106 (56, 157)<0.05
HDL (mg/dL)42 (40, 56)* 36 (31, 48)37 (31, 47)31 (28, 43)<0.05
Total cholesterol (mg/dL) 183 (162, 203) 167 (144, 191)190 (168, 217)187 (155, 214)ns
Triglycerides (mg/dL) 95 (76, 129) 104 (83, 145)136 (101, 221)196 (115, 241)*<0.05
LDL (mg/dL) 114 (96, 122) 97 (75, 140)108 (85, 128)106 (71, 129)ns
TC : HDL ratio(3)3.0 (3.0, 3.8)* 4.4 (3.6, 6.3)3,8 (2.9, 3.9)5.9 (3.2, 6.8)*<0.05
LDL : HDL ratio(3)1,4 (1.0, 2.2)* 2.6 (1.8, 3.2)2.5 (2.0, 3.2)2.9 (2.0, 3.7)<0.05
Note: EFV: efavirenz; NVP: nevirapine; LOP/r: lopinavir/ritonavir; BMI: body mass index (weight/height2 (kg/m2)); PON1: paraoxonase-1;
HDL: high-density lipoprotein; LDL: low-density lipoprotein; ns: no significant difference.
(1)Median (interquartile range (IQR) 25%–75%; 95% confidence interval (CI)).
value: comparison between groups by ANOVA and Tukey's honestly significant difference.
(3)Atherogenic indices.
when comparing with other groups.